Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Conquering oncogenic KRAS and its bypass mechanisms
Pingping Hou, Yingshuang Wang
Theranostics (2022) Vol. 12, Iss. 13, pp. 5691-5709
Open Access | Times Cited: 12

Showing 12 citing articles:

Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 160
Glutamine transporter inhibitor enhances the sensitivity of NSCLC to trametinib through GSDME-dependent pyroptosis
Qingxia Liu, Jinxia Hu, Xuecong Li, et al.
Biochemical Pharmacology (2025) Vol. 233, pp. 116796-116796
Closed Access | Times Cited: 1
Targeting KRAS-G12C in Lung Cancer: The Emerging Role of PROTACs in Overcoming Resistance
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access | Times Cited: 1
Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance
Daiyong Deng, Riya Patel, Cheng-Yao Chiang, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 2952-2952
Open Access | Times Cited: 29
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Wei Ye, Lu Xin, Yue Qiao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189108-189108
Closed Access | Times Cited: 7
Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their anti-tumor activity in RAS-driven cancers
Yiming Miao, Yunpeng Bai, Jinmin Miao, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 15
Open Access | Times Cited: 6
Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS mutations
Gerald P. Linette, Adham S. Bear, Beatriz M. Carreno
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2017-2024
Open Access | Times Cited: 5
NFAT5 governs cellular plasticity-driven resistance to KRAS-targeted therapy in pancreatic cancer
Daiyong Deng, Habeebunnisa Begum, Tong Liu, et al.
The Journal of Experimental Medicine (2024) Vol. 221, Iss. 11
Closed Access | Times Cited: 2
"Activated Translation of HIF-1α mRNA as a Key Mechanism in Oncogenesis of Pancreatic Ductal Adenocarcinoma and Other Malignant Diseases"
Mitsuru Sakitani
Biomedical Journal of Scientific & Technical Research (2023) Vol. 51, Iss. 5
Open Access | Times Cited: 1
MicroRNA-532 as a probable diagnostic and therapeutic marker in cancer patients
Malihe Lotfi, Amirhosein Maharati, Amir Abbas Hamidi, et al.
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis (2024) Vol. 829, pp. 111874-111874
Closed Access
Intersecting evidence: Bibliometric analysis and clinical trials illuminate immunotherapy in KRAS-mutation cancer: A review
Hongyang Liu, Min Qiang, Ying Zhang, et al.
Medicine (2024) Vol. 103, Iss. 36, pp. e39334-e39334
Open Access
Targeting KRAS in gynecological malignancies
Yuanyuan Peng, Qing Yang
The FASEB Journal (2024) Vol. 38, Iss. 19
Open Access
Page 1

Scroll to top